Sana Kliniken AG


Hospital

Location:
Ismaning (head quarters), Germany


Publications in cooperation with FAU scientists


Polykandriotis, E., Horch, R.E., Jost, M., Arkudas, A., Kees, F., & Schmitz, M. (2019). Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy? International Wound Journal, 16(2), 503-510. https://dx.doi.org/10.1111/iwj.13063
Mahfoud, F., Boehm, M., Bongarth, C.M., Bosch, R., Schmieder, R., Schunkert, H.,... Kreutz, R. (2019). Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on themanagement of arterial hypertension. Der Kardiologe, 13(1), 17-23. https://dx.doi.org/10.1007/s12181-019-0300-y
Mahfoud, F., Boehm, M., Bongarth, C.M., Bosch, R., Schmieder, R., Schunkert, H.,... Kreutz, R. (2019). Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the management of arterial hypertension [Kommentar zu den Leitlinien (2018) der Europäischen Gesellschaft für Kardiologie (ESC) und der Europäischen Gesellschaft für Hypertonie (ESH) für das Management der arteriellen Hypertonie]. Internist, 60(4), 424-430. https://dx.doi.org/10.1007/s00108-019-0576-9
Untch, M., Thomssen, C., Bauerfeind, I., Braun, M., Brucker, S.Y., Felberbaum, R.,... Harbeck, N. (2019). Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe und Frauenheilkunde, 79(6), 591-604. https://dx.doi.org/10.1055/a-0897-6457
Schmitt, H., Billmeier, U., Dieterich, W., Rath, T., Sonnewald, S., Reid, S.,... Atreya, R. (2018). IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn's disease patients. (pp. S9-S9).
Loibl, S., Treue, D., Budczies, J., Weber, K., Stenzinger, A., Schmitt, W.D.,... Denkert, C. (2018). Mutational diversity and therapy response in breast cancer-a sequencing analysis in the neoadjuvant GeparSepto trial. In CANCER RESEARCH. Chicago, IL, US: PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
Fasching, P., Decker, T., Guderian, G., Heim, J., Jackisch, C., Lueck, H.-J.,... Woeckel, A. (2018). Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study. In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Mauerer, A., Stenglein, S., Schulz-Drost, S., Schoerner, C., Taylor, D., Krinner, S.,... Forst, R. (2017). Antibacterial Effect of a 4x Cu-TiO2 Coating Simulating Acute Periprosthetic Infection-An Animal Model. Molecules, 22(7). https://dx.doi.org/10.3390/molecules22071042
Siegmund, B., Atreya, R., Bokemeyer, B., Kruis, W., Mudter, J., Sander, C.,... Kucharzik, T. (2016). Biosimilars in inflammatory bowel disease. Zeitschrift für Gastroenterologie, 54(11), 1217-1222. https://dx.doi.org/10.1055/s-0042-117648
Paepke, S., Huober, J., Sherko, K., Eidtmann, H., Untch, M., Costa, S.D.,... Von Minckwitz, G. (2016). Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE). (pp. S98-S99).
De With, K., Allerberger, F., Amann, S., Apfalter, P., Brodt, H.-R., Eckmanns, T.,... Kern, W.V. (2016). Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection, 44(3), 395-439. https://dx.doi.org/10.1007/s15010-016-0885-z
Von Minckwitz, G., Rezai, M., Tesch, H., Huober, J., Gerber, B., Zahm, D.M.,... Loibl, S. (2016). Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). European journal of cancer, 64, 12-21. https://dx.doi.org/10.1016/j.ejca.2016.05.015
Huebner, N.-F., Horch, R.E., Polykandriotis, E., Rau, T., & Dragu, A. (2014). A histopathologic and immunohistochemical study on liquification of human adipose tissue ex vivo. Aesthetic Plastic Surgery, 38(5), 976-84. https://dx.doi.org/10.1007/s00266-014-0371-x
Fasching, P., Jud, S., Hauschild, M., Kuemmel, S., Schuette, M., Warm, M.,... Lux, M.P. (2014). FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer, 14, 66. https://dx.doi.org/10.1186/1471-2407-14-66
Loibl, S., Von Minckwitz, G., Schneeweiss, A., Paepke, S., Lehmann, A., Rezai, M.,... Denkert, C. (2014). PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. Journal of Clinical Oncology, 32(29), 3212-20. https://dx.doi.org/10.1200/JCO.2014.55.7876
Loibl, S., Volz, C., Mau, C., Blohmer, J.-U., Costa, S.D., Eidtmann, H.,... Untch, M. (2014). Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Research and Treatment, 144(1), 153-62. https://dx.doi.org/10.1007/s10549-014-2861-6
Gerber, B., Von Minckwitz, G., Eidtmann, H., Rezai, M., Fasching, P., Tesch, H.,... Untch, M. (2014). Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Annals of Surgical Oncology, 21(8), 2517-24. https://dx.doi.org/10.1245/s10434-014-3606-9
Von Minckwitz, G., Rezai, M., Fasching, P., Huober, J., Tesch, H., Bauerfeind, I.,... Untch, M. (2014). Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology, 25(1), 81-9. https://dx.doi.org/10.1093/annonc/mdt410
Von Minckwitz, G., Loibl, S., Untch, M., Eidtmann, H., Rezai, M., Fasching, P.,... Gerber, B. (2014). Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)+. Annals of Oncology, 25(12), 2363-72. https://dx.doi.org/10.1093/annonc/mdu455

Last updated on 2017-07-02 at 08:21